Medication info

Empagliflozin/Metformin Tablet 12.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
A bilaterally convex oval film-coated tablet with a dark brownish-purple color.
Packaging
60 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6]
Approval status
Active

MFDS item code 202302649 · Approved 2023.09.05

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient’s existing dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Drug Interactions in Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 1) under section 3. Caution in administration to the following patients in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see section 2) under section 2. Do not administer to the following patients in Precautions for Use). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to aid in blood glucose control for patients with type 2 diabetes through the combined administration of empagliflozin and metformin. It is particularly effective for patients who are also adhering to dietary and exercise regimens. Additionally, it is used in adults with cardiovascular disease when blood glucose is not adequately controlled. During use, it is important to monitor the risk of cardiovascular events based on professional guidance. Overall, this medication improves blood glucose control and assists in the treatment of type 2 diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient’s existing dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Drug Interactions in Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 1) under section 3. Caution in administration to the following patients in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see section 2) under section 2. Do not administer to the following patients in Precautions for Use). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and contains components that help control blood glucose levels. Caution should be exercised as this medication may cause a rare side effect known as severe lactic acidosis. Lactic acidosis is a dangerous condition that occurs when there is an excessive buildup of lactic acid in the body, which can be fatal in severe cases. Additionally, co-administration with other diabetes medications like insulin or sulfonylureas may lead to severe hypoglycemia. Patients with moderate to severe renal impairment, acute renal issues, heart failure, acute myocardial infarction, and severe infections should not use this medication. Before and after tests using iodine-based contrast agents, this medication should be temporarily discontinued due to the risk of renal damage and lactic acidosis, and can be resumed only after renal function has returned to normal. Women who are pregnant or may become pregnant, as well as breastfeeding mothers, should not take this medication, nor is it recommended for children or adolescents under 18 years of age. During treatment, regular monitoring of renal function and serum creatinine levels should be conducted to keep track of kidney status, and patients at risk of fluid loss should be particularly cautious. This medication may increase the risk of urinary tract infections and genital infections; if any symptoms of infection appear, patients should inform healthcare providers immediately. Also, the metformin component can cause gastrointestinal disorders (diarrhea, nausea, vomiting, etc.) and reduced absorption of vitamin B12; thus, it may be necessary to check and supplement vitamin B12 levels if needed. Alcohol intake increases the risk of lactic acidosis; therefore, excessive drinking should be avoided during treatment. Patients should be alert for symptoms of hypoglycemia while taking this medication, particularly when co-administered with insulin or sulfonylureas. If surgery is planned, this medication should be stopped 48 hours prior, and can be resumed only after renal function has been confirmed to be normal post-surgery. During treatment, patients should consult a doctor immediately if symptoms such as fever, pain, swelling, or rashes around the genitals or perineum occur, as there is a rare risk of serious perineal necrosis. Elderly patients, especially those over 75 years of age, are at higher risk for fluid loss; therefore, caution is required during treatment, and appropriate dosage adjustments based on renal function are necessary. In cases of overdose, severe side effects such as lactic acidosis may occur, requiring immediate medical treatment, and blood dialysis may be necessary. This medication should be kept out of reach of children and stored in its original container for safety.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • nausea
  • vomiting
  • diarrhea
Show 145 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased fluid volume
  • decreased blood pressure
  • dehydration
  • hypotension
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • vulvar moniliasis
  • vulvitis
  • balanitis
  • perineal necrosis
  • pyelonephritis
  • urosepsis
  • headache
  • dizziness
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epiphysitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • nasopharyngitis
  • shingles
  • drowsiness
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • abnormal sensations
  • swelling
  • pain
  • pain at the injection site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • double vision
  • hypertension
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • position-related dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • prickly heat
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • conjunctival injection
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • lattice retinal detachment
  • eyelid edema
  • vision impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • rib fracture
  • ligamentous strain syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disorders
  • peripheral artery occlusive disease
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is best kept at room temperature between 1 degree and 30 degrees Celsius. Maintaining appropriate temperature and container conditions will safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

A bilaterally convex oval film-coated tablet with a dark brownish-purple color.

Package unit

60 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.